Sign in or create an account to add this stock to your watchlist.
About Cue Biopharma (NASDAQ:CUE)
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers and autoimmune disorders. The company's lead drug candidate includes CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to human papilloma virus related cancers. Its biologics drug candidates also comprise CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. The company also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. Cue Biopharma, Inc. has a collaboration agreement with Merck & Co. for the research and development of its proprietary biologics that target autoimmune disease indications. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$3.17 per share
Price / Book4.43
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Cue Biopharma (NASDAQ:CUE) Frequently Asked Questions
What is Cue Biopharma's stock symbol?
Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE."
How were Cue Biopharma's earnings last quarter?
Who are some of Cue Biopharma's key competitors?
Some companies that are related to Cue Biopharma include Uniqure (QURE), Revance Therapeutics (RVNC), Esperion Therapeutics (ESPR), Retrophin (RTRX), Athenex (ATNX), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), Lexicon Pharmaceuticals (LXRX), Mirati Therapeutics (MRTX), Flexion Therapeutics (FLXN), Alder BioPharmaceuticals (ALDR), Zai Lab (ZLAB), Endocyte (ECYT), Karyopharm Therapeutics (KPTI) and Omeros (OMER).
Who are Cue Biopharma's key executives?
Cue Biopharma's management team includes the folowing people:
- Mr. Daniel R. Passeri M.Sc., MSc., J.D., CEO, Pres & Director (Age 57)
- Mr. Colin G. Sandercock, Sr. VP, Gen. Counsel & Sec. (Age 60)
- Dr. Ronald D. Seidel III, Exec. VP and Head of R&D (Age 42)
- Dr. Rodolfo J. Chaparro, Exec. VP & Head of Immunology (Age 45)
- Dr. Steven C. Almo, Founder and Chairman of Scientific & Clinical Advisory Board (Age 57)
Has Cue Biopharma been receiving favorable news coverage?
News articles about CUE stock have been trending somewhat positive on Tuesday, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cue Biopharma earned a daily sentiment score of 0.15 on Accern's scale. They also assigned news coverage about the company an impact score of 46.62 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Cue Biopharma's major shareholders?
Cue Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include First Eagle Investment Management LLC (2.48%), BlackRock Inc. (1.96%), Northern Trust Corp (0.37%), Citigroup Inc. (0.28%), Schwab Charles Investment Management Inc. (0.08%) and California State Teachers Retirement System (0.07%). View Institutional Ownership Trends for Cue Biopharma.
Which institutional investors are buying Cue Biopharma stock?
CUE stock was purchased by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, BlackRock Inc., Northern Trust Corp, Citigroup Inc., Schwab Charles Investment Management Inc., California State Teachers Retirement System and The Manufacturers Life Insurance Company . View Insider Buying and Selling for Cue Biopharma.
How do I buy shares of Cue Biopharma?
Shares of CUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cue Biopharma's stock price today?
One share of CUE stock can currently be purchased for approximately $14.05.
How big of a company is Cue Biopharma?
Cue Biopharma has a market capitalization of $289.88 million. Cue Biopharma employs 30 workers across the globe.
How can I contact Cue Biopharma?
Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 781-305-7777.
MarketBeat Community Rating for Cue Biopharma (CUE)MarketBeat's community ratings are surveys of what our community members think about Cue Biopharma and other stocks. Vote "Outperform" if you believe CUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cue Biopharma (NASDAQ:CUE) Analyst Ratings History
(Data available from 5/22/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Cue Biopharma (NASDAQ:CUE) Earnings History and Estimates Chart
Cue Biopharma (NASDAQ CUE) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Cue Biopharma (NASDAQ:CUE) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Cue Biopharma (NASDAQ CUE) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 9.14%
Cue Biopharma (NASDAQ CUE) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Cue Biopharma (NASDAQ CUE) News Headlines
Cue Biopharma (NASDAQ:CUE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Cue Biopharma (NASDAQ CUE) Stock Chart for Tuesday, May, 22, 2018